Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) Debt to Equity (2021 - 2025)

Legend Biotech filings provide 5 years of Debt to Equity readings, the most recent being $0.3 for Q1 2025.

  • On a quarterly basis, Debt to Equity rose 22.1% to $0.3 in Q1 2025 year-over-year; TTM through Mar 2025 was $0.3, a 22.1% increase, with the full-year FY2024 number at $0.29, up 28.76% from a year prior.
  • Debt to Equity hit $0.3 in Q1 2025 for Legend Biotech, up from $0.29 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.41 in Q1 2023 to a low of $0.05 in Q2 2021.
  • Median Debt to Equity over the past 5 years was $0.25 (2024), compared with a mean of $0.24.
  • Biggest five-year swings in Debt to Equity: surged 138.08% in 2023 and later tumbled 39.56% in 2024.
  • Legend Biotech's Debt to Equity stood at $0.16 in 2021, then soared by 122.9% to $0.35 in 2022, then tumbled by 35.87% to $0.22 in 2023, then rose by 28.76% to $0.29 in 2024, then grew by 3.78% to $0.3 in 2025.
  • The last three reported values for Debt to Equity were $0.3 (Q1 2025), $0.29 (Q4 2024), and $0.27 (Q3 2024) per Business Quant data.